Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees

PLoS Computational Biology

Volumn 11, Issue 4, 2015, Pages

  Choi, Ickwon ^a   Chung, Amy W ^b   Suscovich, Todd J ^b   Rerks Ngarm, Supachai ^c   Pitisuttithum, Punnee ^d   Nitayaphan, Sorachai ^e   Kaewkungwal, Jaranit ^d   O'Connell, Robert J ^e   Francis, Donald ^f   Robb, Merlin L ^g,h   Michael, Nelson L ^g   Kim, Jerome H ^g   Alter, Galit ^b   Ackerman, Margaret E ⁱ   Bailey Kellogg, Chris ^a  

^a Dartmouth Department of Computer Science_Dartmouth College   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^f Global Solutions for Infectious Diseases   (United States)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h Henry Jackson Foundation   (United States)

ⁱ DARTMOUTH COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; ARTIFICIAL INTELLIGENCE; CYTOTOXICITY; LEARNING SYSTEMS; VACCINES;

ADAPTIVE IMMUNE RESPONSE; CELL RESPONSE; CELLULARS; EFFECTOR CELLS; FEATURE FUNCTION; FUNCTION RELATIONSHIPS; IMMUNE EFFECTOR CELLS; INNATE IMMUNES; MACHINE LEARNING METHODS; PREDICTIVE MODELS;

ANTIBODIES;

CYTOKINE; ERDOSTEINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL PHAGOCYTOSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INNATE IMMUNITY; MACHINE LEARNING; MAJOR CLINICAL STUDY; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECIPIENT; RISK REDUCTION; VACCINATION; BIOLOGICAL MODEL; BIOLOGY; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

AIDS VACCINES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMPUTATIONAL BIOLOGY; CYTOKINES; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; MACHINE LEARNING; MODELS, IMMUNOLOGICAL;

EID: 84929485998     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004185     Document Type: Article

References (38)

1. Plotkin SA, Correlates of protection induced by vaccination. Clin Vaccine Immunol CVI. 2010;17: 1055–1065. doi: 10.1128/CVI.00131-10 20463105
2. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6: 207–210. doi: 10.1038/72318 10655111
3. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet. 3;380: 1559–1567. doi: 10.1016/S0140-6736(12)61428-7
4. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med. 2015;372: 113–123. doi: 10.1056/NEJMoa1411037 25365753
5. McCoy LE, Weiss RA, Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med. 2013;210: 209–223. doi: 10.1084/jem.20121827 23401570
6. Richman DD, Wrin T, Little SJ, Petropoulos CJ, Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100: 4144–4149. doi: 10.1073/pnas.0630530100 12644702
7. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;advance online publication. doi: 10.1038/nature13036
8. Liao H-X, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496: 469–476. doi: 10.1038/nature12053 23552890
9. Kwong PD, Mascola JR, Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012;37: 412–425. doi: 10.1016/j.immuni.2012.08.012 22999947
10. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L, Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011;7: e1001251. doi: 10.1371/journal.ppat.1001251 21249232
11. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med. 1999;5: 204–210. doi: 10.1038/5568 9930869
12. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194: 1661–1671. doi: 10.1086/508748 17109337
13. Ackerman ME, Dugast A-S, Alter G, Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu Rev Med. 2012;63: 113–130. doi: 10.1146/annurev-med-050310-085221 22077718
14. Brown EP, Licht AF, Dugast A-S, Choi I, Bailey-Kellogg C, Alter G, et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods. 2012;386: 117–123. doi: 10.1016/j.jim.2012.09.007 23023091
15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361: 2209–2220. doi: 10.1056/NEJMoa0908492 19843557
16. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366: 1275–1286. doi: 10.1056/NEJMoa1113425 22475592
17. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490: 417–420. doi: 10.1038/nature11519 22960785
18. Yates NL, Liao H-X, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Sci Transl Med. 2014;6: 228ra39–228ra39. doi: 10.1126/scitranslmed.3007730 24648342
19. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol Baltim Md 1950. 1996;157: 2168–2173. 8757343
20. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. 1999;180: 1338–1341. doi: 10.1086/314988 10479168
21. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 1999. 2011;58: 127–131. doi: 10.1097/QAI.0b013e31822c62b9 21792067
22. Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013;123: 2183–2192. doi: 10.1172/JCI65708 23563315
23. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al. Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines. Sci Transl Med. 2014;6: 228ra38. doi: 10.1126/scitranslmed.3007736 24648341
24. Ackerman ME, Moldt B, Wyatt RT, Dugast A- S, McAndrew E, Tsoukas S, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366: 8–19. doi: 10.1016/j.jim.2010.12.016 21192942
25. Gómez-Román VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods. 2006;308: 53–67. doi: 10.1016/j.jim.2005.09.018 16343526
26. Bruhns P, Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012;119: 5640–5649. doi: 10.1182/blood-2012-01-380121 22535666
27. Friedman JH, Hastie T, Tibshirani R, Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;33. Available: http://www.jstatsoft.org/v33/i01/ 20808728
28. Ward JH, Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963;58: 236–244. doi: 10.2307/2282967
29. Charrad M, Ghazzali N, Boiteau V, Niknafs A, NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set. J Stat Softw. 2014;61. Available: http://www.jstatsoft.org/v61/i06
30. Goeman JJ, L1 penalized estimation in the Cox proportional hazards model. Biom J Biom Z. 2010;52: 70–84. doi: 10.1002/bimj.200900028 19937997
31. Deng H, Runger G, Feature selection via regularized trees. The 2012 International Joint Conference on Neural Networks (IJCNN). 2012. pp. 1–8. doi: 10.1109/IJCNN.2012.6252640
32. Cortes C, Vapnik V, Support-Vector Networks. Mach Learn. 1995;20: 273–297. doi: 10.1023/A:1022627411411
33. Scholkopf B, Smola AJ, Williamson RC, Bartlett PL, New support vector algorithms. Neural Comput. 2000;12: 1207–1245. 10905814
34. Chang C-C, Lin C-J, LIBSVM: A Library for Support Vector Machines. ACM Trans Intell Syst Technol. 2011;2: 1–27. doi: 10.1145/1961189.1961199
35. Tibshirani R, Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol. 1996; 267–288.
36. Efron B, Hastie T, Johnstone I, Tibshirani R, Least angle regression. Ann Stat. 200404;32: 407–499. doi: 10.1214/009053604000000067
37. Williams CKI, Rasmussen CE, Gaussian Processes for Regression. Advances in Neural Information Processing Systems 8. MIT press; 1996. pp. 514–520.
38. Drucker H, Burges CJC, Kaufman L, Smola A, Vapnik V, Support Vector Regression Machines. Adv Neural Inf Process Syst 9. 1997;9: 155–161.